Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.

Animals Biomarkers, Tumor Cisplatin / pharmacology Disease Models, Animal Drug Resistance, Neoplasm / drug effects Female Furans / pharmacology Humans Ketones / pharmacology Mice Paclitaxel / pharmacology Treatment Outcome Triple Negative Breast Neoplasms / drug therapy Tumor Burden / drug effects Tumor Cells, Cultured Xenograft Model Antitumor Assays
PDOX TNBC cisplatinum eribulin matrix-producing breast carcinoma patient-derived orthotopic xenograft triple-negative breast cancer tumor regression

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
May 2020
Historique:
received: 06 03 2020
revised: 18 03 2020
accepted: 19 03 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 19 5 2020
Statut: ppublish

Résumé

Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triple-negative breast cancer (TNBC). In the present report, we determined the drug sensitivity for a triple-negative MPBC using a patient-derived orthotopic xenograft (PDOX) model. The PDOX model was established in the left 2 The MPBC PDOX model was resistant to cisplatinum (p=0.800). Paclitaxel suppressed tumor growth compared to the control group (p=0.009). However, only eribulin regressed the tumor (p=0.001). Eribulin has clinical potential for triple-negative MPBC patients.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triple-negative breast cancer (TNBC). In the present report, we determined the drug sensitivity for a triple-negative MPBC using a patient-derived orthotopic xenograft (PDOX) model.
MATERIALS AND METHODS METHODS
The PDOX model was established in the left 2
RESULTS RESULTS
The MPBC PDOX model was resistant to cisplatinum (p=0.800). Paclitaxel suppressed tumor growth compared to the control group (p=0.009). However, only eribulin regressed the tumor (p=0.001).
CONCLUSION CONCLUSIONS
Eribulin has clinical potential for triple-negative MPBC patients.

Identifiants

DOI: 10.21873/anticanres.14217 PMID: 32366391
pubmed: 32366391
pii: 40/5/2475
doi: 10.21873/anticanres.14217
doi:

Substances chimiques

Biomarkers, Tumor 0
Furans 0
Ketones 0
eribulin LR24G6354G
Paclitaxel P88XT4IS4D
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2475-2479

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Jun Yamamoto (J)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.
Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Takuya Murata (T)

Department of Obstetrics and Gynecology 2, Kawasaki Medical School, Okayama, Japan.

Norihiko Sugisawa (N)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Takashi Higuchi (T)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Yoshihiko Tashiro (Y)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Hiroto Nishino (H)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Sachiko Inubushi (S)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Y U Sun (YU)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Hyein Lim (H)

AntiCancer Inc, San Diego, CA, U.S.A.
Department of Surgery, University of California, San Diego, CA, U.S.A.

Kentaro Miyake (K)

Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Koichiro Shimoya (K)

Department of Obstetrics and Gynecology 1, Kawasaki Medical School, Kurashiki, Japan.

Tsunehisa Nomura (T)

Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan.

Junichi Kurebayashi (J)

Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan.

Hirokazu Tanino (H)

Breast Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

Chihiro Hozumi (C)

AntiCancer Japan Inc, Narita, Japan.

Michael Bouvet (M)

Department of Surgery, University of California, San Diego, CA, U.S.A.

Shree Ram Singh (SR)

Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com singhshr@mail.nih.gov endoit@yokohama-cu.ac.jp.

Itaru Endo (I)

Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan all@anticancer.com singhshr@mail.nih.gov endoit@yokohama-cu.ac.jp.

Robert M Hoffman (RM)

AntiCancer Inc, San Diego, CA, U.S.A. all@anticancer.com singhshr@mail.nih.gov endoit@yokohama-cu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du platine › Cisplatine › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Furanes › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Composés chimiques organiques › Cétones › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Paclitaxel › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Tumeurs du sein triple-négatives › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Techniques d'investigation › Charge tumorale › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Eribulin Regresses a Cisplatinum-resistant...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Eribulin Regresses a Cisplatinum-resistant...